RxDoctor Payments Data

Scott Gardner, MD

Ophthalmology · Fayetteville, GANPI 1457613655

Payments from drug & device makers

$4,681in general payments, 2019–2025

Across 208 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$1K
  • AbbVie$627
  • Alcon$450
  • Novartis$383
  • Oyster Point Pharma, Inc.$339
  • Bausch & Lomb Americas Inc.$291
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$4,667100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,681 in reported general payments places this provider in the 70th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$412,954
Medicare patients
1,379
Services billed
3,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine137$149,596
LumiganBimatoprost256$143,692
Cyclosporine134$95,596
XiidraLifitegrast51$77,039
MieboPerfluorohexyloctane/Pf29$29,603
CequaCyclosporine26$27,260
RhopressaNetarsudil Mesylate38$23,799
TyrvayaVarenicline Tartrate21$20,108
CombiganBrimonidine Tartrate/Timolol48$18,754
Prednisolone Acetate246$10,097
Alphagan PBrimonidine Tartrate13$8,711
ZioptanTafluprost/Pf14$8,472
SimbrinzaBrinzolamide/Brimonidine Tart30$8,206
Latanoprost524$6,939
IyuzehLatanoprost/Pf16$6,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$627$320,753454 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$291$106,64280 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$40$30,07953 claims
Sun Pharmaceutical Industries Inc.Cequa$1,002$27,26026 claims
Oyster Point Pharma, Inc.Tyrvaya$339$20,10821 claims
AlconSimbrinza$450$8,20630 claims
Thea Pharma Inc.Iyuzeh$79$6,54316 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$122$3,98916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →